For decades, breast cancer radiotherapy meant 25–28 sessions spread over five to six weeks. For patients travelling from outside Kathmandu — or from India seeking affordable care — this schedule posed a real hardship. Hypofractionation changes that equation by delivering a higher dose per session, completing treatment in three weeks or fewer, with equivalent cancer control and similar or better side-effect profiles.
What Is Hypofractionation?
Conventional radiotherapy typically delivers 1.8–2 Gy per fraction. Hypofractionation delivers 2.4–3.3 Gy per fraction, exploiting the favourable radiobiology of breast cancer (low α/β ratio ~3–4 Gy) to compress the course without sacrificing tumour control. Two landmark regimens now define standard practice globally:
- UK START-B: 40 Gy in 15 fractions over 3 weeks — equivalent 10-year outcomes to conventional 50 Gy/25#.
- FAST-Forward: 26 Gy in 5 weekly fractions — non-inferior at 5 years, now endorsed by ASTRO, ESMO, and ESTRO.
- Ultra-hypofractionation (5 daily fractions): Emerging data from MSKCC and Christie; KCC is following trial maturation before routine adoption.
The Evidence Base
The 2023 ASTRO guidelines on breast hypofractionation give a strong recommendation for moderately hypofractionated whole-breast irradiation (WBI) for virtually all patients requiring adjuvant radiotherapy after breast-conserving surgery, regardless of age, tumour grade, receipt of chemotherapy, or laterality. The data convincingly show no meaningful difference in local recurrence, survival, or late toxicity — including cardiac dose for left-sided cancers when IMRT/VMAT planning is used.
Who Is a Good Candidate?
Most patients requiring adjuvant WBI after breast-conserving surgery qualify. Hypofractionation is also increasingly used after mastectomy (post-mastectomy radiotherapy, PMRT) and for regional nodal irradiation. Relative considerations include:
- Breast size: Large, pendulous breasts may have greater dose inhomogeneity — VMAT planning mitigates this at KCC.
- Simultaneous integrated boost (SIB): Tumour bed boost can be delivered concurrently, avoiding extra fractions.
- Implant reconstruction: Still evolving — discuss with your radiation oncologist.
- Bilateral breast cancer: Cardiac constraints require careful dosimetric review.
Why Does This Matter for Patients in Nepal?
Nepal's cancer burden is rising, with breast cancer now the most common cancer in women. Many patients travel from Terai, hill districts, or even India for treatment. A 15-fraction course over three weeks versus 25 fractions over five weeks translates directly to lower travel costs, fewer days of lost income, and faster return to family and work. For patients deciding between treatment in Nepal versus India, KCC's hypofractionation capability and VMAT infrastructure close the gap with tertiary Indian centres — at a fraction of the cost.
A short explainer on hypofractionated radiotherapy for breast cancer patients — in plain language.
What to Expect at KCC
Patients referred for adjuvant breast radiotherapy at KCC undergo a CT simulation (planning scan), followed by 3–5 working days of dosimetric planning. Treatment is then delivered on our Varian linear accelerator using VMAT. A typical 15-fraction course runs Monday–Friday over three weeks. Side effects during treatment include mild skin redness (erythema) and fatigue; late effects such as fibrosis are low with modern dosimetry.
Key Takeaways
- Hypofractionated radiotherapy (15 fractions, 3 weeks) is the global standard for most breast cancer patients after breast-conserving surgery.
- Cancer control rates are equivalent to conventional 25-fraction courses; side effects are similar or better.
- KCC has delivered VMAT-based hypofractionation since 2019 — it is our institutional standard, not a pilot.
- Shorter courses reduce travel burden and cost, making KCC an accessible choice for patients across Nepal and from India.
- Eligibility should be confirmed with your radiation oncologist; most patients with early to locally advanced breast cancer qualify.
References
